Foluso Ademuyiwa

Medicine & Life Sciences

1. Breast Neoplasms 100%
2. Triple Negative Breast Neoplasms 68%
3. Drug Therapy 25%
4. Estrogen Receptors 22%
5. palbociclib 21%
6. Neoplasms 19%
7. African Americans 17%
8. eribulin 15%
9. Circulating Tumor DNA 14%
10. Trastuzumab 14%
11. Mutation 13%
12. Neoadjuvant Therapy 13%
13. Recurrence 10%
14. Genetic Testing 10%
15. Survival 10%
16. Anastrozole 10%
17. Sentinel Lymph Node Biopsy 10%
18. Therapeutics 10%
19. African Continental Ancestry Group 9%
20. Lobular Carcinoma 9%
21. Non-Small Cell Lung Carcinoma 9%
22. Adjuvant Chemotherapy 8%
23. Progesterone Receptors 8%
24. Aromatase Inhibitors 8%
25. European Continental Ancestry Group 8%
26. balixafortide 8%
27. Genes 7%
28. Confidence Intervals 7%
29. POL5551 7%
30. Clinical Trials 7%
31. Arthralgia 7%
32. Oncologists 7%
33. Docetaxel 6%
34. erbB-2 Genes 6%
35. Hepatocyte Nuclear Factor 3-alpha 6%
36. taxane 6%
37. Biomarkers 6%
38. Letrozole 6%
39. Mortality 6%
40. Vitamin D 6%
41. NVP-BKM120 6%
42. Fulvestrant 5%
43. Breast 5%
44. Neoplasm Metastasis 5%
45. Anthracyclines 5%
46. Cyclin-Dependent Kinase 6 5%
47. Proteogenomics 5%
48. thymidine kinase 1 5%
49. MK 2206 5%
50. ramucirumab 5%